NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Jonas DE, Wines RCM, DelMonte M, et al. Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet]. Portland (OR): Oregon Health & Science University; 2011 Apr.
This publication is provided for historical reference only and the information may be out of date.
Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet].
Show detailsTable H-1. Strength of evidence for the comparative efficacy of inhaled corticosteroids
Table H-2. Strength of evidence for the comparative efficacy of leukotriene modifiers (LMs)
Table H-3. Strength of evidence for the comparative efficacy of LABAs
Table H-4. Strength of evidence for the comparative efficacy of omalizumab and placebo
Table H-5. Strength of evidence for the comparative efficacy of BUD/FM and FP/SM
Table H-7. Strength of evidence for the comparative efficacy of ICSs and LTRAs
Table H-8. Strength of evidence for the comparative efficacy of ICSs and LABAs for monotherapy
Table H-13. Strength of evidence for the comparative efficacy of ICS + LTRA and ICS
Table H-14. Strength of evidence for the comparative efficacy of LABA + ICS and LTRA
Table H-15. Strength of evidence for the comparative efficacy of LTRA + ICS and LABA + ICS
Table H-16. Strength of evidence for the comparative efficacy of ICS + LABA and LTRA + LABA
- Strength of evidence - Drug Class Review: Controller Medications for AsthmaStrength of evidence - Drug Class Review: Controller Medications for Asthma
Your browsing activity is empty.
Activity recording is turned off.
See more...